In addition, the association of the KRAS-variant primarily with postmenopausal ovarian cancer suggests that oophorectomy might be reasonable delayed in these patients compared to recommendations for women with BRCA mutations, where oophorectomy is recommended at 35 or upon completion of childbearing. This evidence concerns the gene KRAS and ovarian cancer.